Explore how utilizing technologies like AI and digital twinning can inform decision-making at the R&D stage and how to optimize the delivery of the final drug product with greener logistics and learn more about selecting a partner who shares the same environmental priorities.
Glioblastoma multiforme (GBM) is the most common type of malignant primary brain tumor. It is difficult to treat and has a high risk of recurrence after surgery, placing efficacious treatments in high demand. Discover new possibilities for increased dosing capabilities and diffusion across the brain parenchyma offered by nanoformed APIs.
Optimizing a drug’s solid form can improve its solubility and bioavailability when further molecular modifications are prohibitive. The Nanoform team reviews solid form strategies for increasing the solubility and oral bioavailability of small molecule drugs.
Discover how incorporating GMP expertise alongside novel technologies that can enhance the properties of active pharmaceutical ingredients (APIs) and dosage forms holds promise for viable clinical and commercial success.
Nanoform’s award-winning CESS® technology is a bottom-up nanoparticle engineering approach that enables the creation of API nanoparticles and can unlock the full therapeutic potential of small molecule drugs.
